You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKesson
Colorcon
Dow
Boehringer Ingelheim

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for BGB-3111

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for BGB-3111?

BGB-3111 is an investigational drug.

There have been 79 clinical trials for BGB-3111. The most recent clinical trial was a Phase 1 trial, which was initiated on November 2nd 2017.

The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Carcinoma. The leading clinical trial sponsors are BeiGene, BeiGene USA, Inc., and M.D. Anderson Cancer Center.

There are five US patents protecting this investigational drug and thirty-eight international patents.

Recent Clinical Trials for BGB-3111
TitleSponsorPhase
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)BeiGenePhase 2
Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial CarcinomaSun Yat-sen UniversityPhase 2
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell MalignanciesBeiGenePhase 1

See all BGB-3111 clinical trials

Clinical Trial Summary for BGB-3111

Top disease conditions for BGB-3111
Top clinical trial sponsors for BGB-3111

See all BGB-3111 clinical trials

US Patents for BGB-3111

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGB-3111   Start Trial Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BEIGENE, LTD. (Grand Cayman, KY)   Start Trial
BGB-3111   Start Trial Treatment of pemphigus PRINCIPIA BIOPHARMA INC. (South San Francisco, CA)   Start Trial
BGB-3111   Start Trial Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators BEIGENE SWITZERLAND GMBH (Basel, CH)   Start Trial
BGB-3111   Start Trial Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BeiGene, Ltd. (George Town, KY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BGB-3111

Drugname Country Document Number Estimated Expiration Related US Patent
BGB-3111 Australia 2014256633 2033-04-25   Start Trial
BGB-3111 Brazil 112015025260 2033-04-25   Start Trial
BGB-3111 Canada 2902686 2033-04-25   Start Trial
BGB-3111 China 104884458 2033-04-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKesson
Colorcon
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.